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Statins and Ventricular Arrhythmias in Nonischemic Cardiomyopathy August 21, 2012:749–55Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated
Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter
Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)
Objectives This study hypothesized that time-dependent statin therapy will reduce the risk of life-threatening ventricu-
lar tachyarrhythmias among patients with nonischemic cardiomyopathy (NICM) enrolled in the MADIT-CRT
(Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy).
Background Prior studies suggested that statin therapy exerts antiarrhythmic properties among patients with coronary
artery disease. However, data regarding the effect of statins on arrhythmic risk among patients with NICM
are limited.
Methods Multivariate Cox proportional hazards regression modeling was used to assess the effect of statin therapy,
evaluated as a time-dependent covariate, on the risk of appropriate defibrillator therapy for fast ventricular
tachycardia (VT) (defined as a rate faster than 180 beats/min)/ventricular fibrillation (VF) or death (primary end-
point) and appropriate defibrillator shocks (secondary endpoint) among 821 patients with NICM enrolled in the
MADIT-CRT trial.
Results Statin users (n  499) were older and had a higher prevalence of diabetes and hypertension yet were less fre-
quently smokers. Multivariate analysis showed that time-dependent statin therapy was independently associated
with a significant 77% reduction in the risk of fast VT/VF or death (p  0.001) and with a significant 46% reduc-
tion in the risk of appropriate implantable cardioverter defibrillator shocks (p  0.01). Consistent with these
findings, the cumulative probability of fast VT/VF or death at 4 years of follow-up was significantly lower among
patients who were treated with statins (11%) as compared with study patients who were not treated with statins
(19%; p  0.006 for the overall difference during follow-up).
Conclusions Statin use was associated with a significant reduction in the risk of life-threatening ventricular tachyarrhythmias among
patients with NICM. (J Am Coll Cardiol 2012;60:749–55) © 2012 by the American College of Cardiology FoundationM
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tCoronary artery disease is the underlying etiology for
approximately 80% of fatal ventricular arrhythmias, the
remainder being accounted for by other pathological con-
ditions involving the myocardium (1).
The protective effect against ventricular tachycardia (VT)/
ventricular fibrillation (VF) attributed to use of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase-inhibitors (statins) has
been described in numerous studies (2–8). However, because
these studies enrolled mainly patients with coronary artery
disease, scarce data exist regarding this effect in nonischemic
cardiomyopathy (NICM) patients. A sub analysis of the
DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy
Treatment Evaluation) trial suggested a trend toward a reduc-
tion in the risk of arrhythmic sudden death among statin users,
yet there was no difference in the rate of appropriate implant-
able cardioverter-defibrillator (ICD) shocks (9).
The MADIT-CRT (Multicenter Automatic Defibrillator
Implantation Trial with Cardiac Resynchronization Therapy)
enrolled mildly symptomatic heart failure patients with isch-
emic cardiomyopathy (n  999) and NICM (n  821) who
ere randomized to cardiac resynchronization therapy with a
efibrillator (CRT-D) or to defibrillator-only therapy (10).
he aim of the present study was to evaluate the effect of statin
herapy on the risk for life-threatening ventricular tachyar-
hythmias among NICM patients enrolled in the MADIT-
RT trial. pethods
tudy design and population. The design and results of
he MADIT-CRT trial were previously published (10).
riefly, study patients were randomly assigned in a 3:2 ratio
o receive either CRT-D or ICD. Patients who were at least
1 years of age were enrolled if they had ischemic cardio-
yopathy (New York Heart Association functional class I
r II) or NICM (New York Heart Association functional
lass II only), sinus rhythm, left ventricular ejection fraction
30%, and a prolonged QRS duration of 130 ms. An
ICM diagnosis was based on the absence of: 1) a
ocumented history of a prior infarction (Q-wave or
nzyme positive); 2) a history of a coronary revascular-
zation procedure (coronary artery bypass graft surgery,
alloon and/or stent angioplasty); and 3) documented
ignificant (50%) stenosis in a major epicardial coronary
rtery at angiography and history of angina pectoris or
ther coronary-related symptoms or signs. These criteria
ere evaluated in each follow-up examination and by the
reating physician. No patients developed ischemic cor-
nary artery disease during follow-up according to the
forementioned definitions, and hence none were ex-
luded from the analysis for this reason. Follow-up data
ncluded detailed information of drug therapy during the
rial. Statin therapy (type of drug and dosage) was
rescribed at the discretion of the treating physician.
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August 21, 2012:749–55 Statins and Ventricular Arrhythmias in Nonischemic CardiomyopathyThe protocol was approved by the institutional review
board at each participating organization, and each patient
provided written informed consent before enrollment.
Commercially available devices (Boston Scientific,
Natick, Massachusetts) were used in the trial. Device testing
and programming were performed as reported (10). The
configuration used a VT zone set at 170 beats/min and a VF
zone set at 230 beats/min. Fast VT was defined as a
ventricular rate faster than 180 beats/min. The ICDs were
interrogated quarterly and after the occurrence of device
therapy at a core laboratory for arrhythmia adjudication and
categorization. Ventricular tachycardia was defined as ven-
tricular rate up to 250 beats/min; VF was defined as
ventricular rate faster than 250 beats/min with disorganized
ventricular electrograms.
Endpoints. The primary endpoint of the present study was
he first occurrence of appropriate defibrillator therapy for
ast VT/VF or death, whichever occurred first. Death was
ncluded in the primary endpoint to avoid a possible bias of
AQ:2Baseline Clinical Characteristics of Study PTable 1 Baseline Clinical Characteristics of
Variable
Age, yrs
Female
Randomization to CRTD treatment arm
QRS duration, ms
NYHA functional class III or IV 3 months before enrollmen
Past history of ventricular arrhythmias
Past history of atrial arrhythmias
Diabetes mellitus
Hypertension
Blood pressure, mm Hg
Systolic
Diastolic
Cigarette smoking
Blood urea nitrogen 26 mg/dl (9.3 mmol/l)
Creatinine, mg/dl
Right bundle branch block
Left bundle branch block
Body mass index 30 kg/m2
Drug therapy used
Class 1 antiarrhythmic agents
Amiodarone
Aldosterone antagonists
Beta-blocking agents
Digoxin
Angiotensin-converting enzyme inhibitor
Angiotensin-receptor-blocker
Diuretics
Echocardiographic parameters
Left ventricular ejection fraction, %
Left ventricular end-systolic volume index (ml/m2)
Left ventricular end-diastolic volume index (ml/m2)
Left atrial volume index (ml/m2)Values are mean  SD or % (n).
CRTD  cardiac resynchronization therapy with a defibrillator; NYHA  Necensoring fatal arrhythmic events
that were not interrogated. The
mode of death was adjudicated
by the mortality committee with
the modified Hinkle-Thaler clas-
sification (11). The secondary
endpoints of the study included
the first occurrence of an appro-
priate defibrillator shock during
the trial and the first occurrence
of defibrillator therapy for fast
VT/VF or for VF only.
Statistical analysis. The chi-
square test was used for the com-
parison of categorical variables, and the nonparametric
Wilcoxon rank sum test was used for continuous variables
(assessed as mean  SD). The cumulative probabilities for
he first occurrence of the endpoints by treatment with
tatins were assessed according to the method of Kaplan and
ts by Statin Usage at Enrollmenty Patients by Statin Usage at Enrollment
Statin Users
(n  499)
Statin Nonusers
(n  322) p Value
63 10 59 12 0.001
37 (184) 42 (135) 0.15
62 (309) 58 (187) 0.32
164 20 162 20 0.21
12 (60) 10 (32) 0.43
4 (20) 6 (19) 0.26
10 (49) 6 (19) 0.12
37 (184) 16 (51) 0.001
63 (314) 50 (161) 0.001
122 16 121 17 0.90
71 10 72 10 0.18
8 (40) 13 (42) 0.03
22 (110) 17 (54) 0.10
1.1 0.3 1.07 0.3 0.05
3 (15) 4 (13) 0.45
91 (454) 89 (287) 0.26
39 (194) 35 (113) 0.28
0.4 (2) 0.3 (1) 0.46
4 (19) 5 (17) 0.36
39 (194) 39 (126) 0.90
95 (474) 94 (303) 0.42
28 (139) 35 (112) 0.03
77 (384) 79 (254) 0.46
23 (114) 21 (67) 0.47
69 (344) 67 (215) 0.44
29 3 29 4 0.50
89 25 92 26 0.09
125 31 129 32 0.50
45 9 47 10 0.02
Abbreviations
and Acronyms
CRT-D  cardiac
resynchronization therapy
with a defibrillator
ICD  implantable
cardioverter-defibrillator
NICM  nonischemic
cardiomyopathy
VF  ventricular fibrillation
VT  ventricular
tachycardiaatienStud
tw York Heart Association functional class.
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rank test and comparison at specific time points with a
z-test. Kaplan-Meier analyses were carried out as follows:
1) for patients who were treated with statins at baseline,
follow-up in the survival analysis was censored at the time in
which statin therapy was terminated during follow-up; and
2) for patients who did not receive statin therapy at baseline,
follow-up was censored at the time in which statin therapy
was initiated during follow-up. Multivariate regression
models were developed with Cox proportional hazards
regression. Covariates included in the model were identified
with a best subset procedure among variables that were
unbalanced between statin users and nonusers as predictive
of the primary endpoint, fast VT/VF, or death. The
covariates used in the multivariate model were age, diabetes
mellitus, hypertension, left ventricular end-systolic volume
indexed to body surface area, and resynchronization treat-
ment. Statin therapy was assessed in the multivariate model
in a time-dependent manner (i.e., by incorporating in the
Cox model data for each patient that identifies the effect of
each follow-up time “on” and “off” statin therapy during the
trial). The effects of time-dependent statin therapy on the
endpoints in each treatment arm were assessed with
interaction-term analysis. All p values were 2-sided, and a
p value 0.05 was considered significant. Analyses were
conducted with SAS software (version 9.2, SAS Institute,
Cary, North Carolina).
Results
The baseline clinical and echocardiographic patient charac-
teristics stratified by statin therapy are shown in Table 1.
Among MADIT-CRT patients with NICM, 499 (61%)
were statin users. Statin users were older and more fre-
quently had diabetes and hypertension. Statin nonusers
more frequently smoked and used digoxin, and their in-
Figure 1 Cumulative Probability for the Occurrence
of Fast VT/VF or Death by Statin Treatment
Follow-up is censored upon change in statin usage after enrollment. *See
Table 2 for multivariate model details. VF  ventricular fibrillation; VT  ventric-
ular tachycardia.dexed left atrial volume was higher.Effect of statins on fast ventricular tachyarrhythmias.
During follow-up, a total of 158 confirmed events of VT
and VF were documented, of which 49 were further
categorized as fast VT; a total of 139 appropriate shocks
were delivered and 32 (3.9%) patients died.
The mean tachycardia cycle length was significantly
longer among statin users (308 vs. 268 ms, p  0.02).
The cumulative probabilities of time to the combined
endpoint by statin usage at enrollment and follow-up
censored upon change in medication usage is presented in
Figure 1. Statin users had a lower cumulative probability of
fast VT/VF or death (11% compared with 19% at 4 years of
follow-up; unadjusted p log-rank  0.006). The corre-
sponding results for the combined outcome of fast VT/VF
or sudden cardiac death were very similar (10% compared
with 17.5% for nonusers, p  0.007). The cumulative
probabilities of time to fast VT/VF and to VF only by statin
usage are presented in Figures 2A and 2B, respectively.
Statins users had a lower cumulative probability of fast
VT/VF events (6% compared with 10% in nonusers, unad-
justed p log-rank  0.003) and lower probability of VF
events (6% compared with 9% among nonusers, unadjusted
Figure 2 Cumulative Probability for the
Occurrence of Fast VT/VF by Statin Treatment
Cumulative probability for the occurrence of fast VT/VF by statin treatment (A)
and the probability for the occurrence of VF by statin treatment (B). Follow-up
is censored upon change in statin usage after enrollment. *See Table 2 for
multivariate model details. Abbreviations as in Figure 1.
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August 21, 2012:749–55 Statins and Ventricular Arrhythmias in Nonischemic Cardiomyopathyp log-rank  0.045). Accordingly, patients treated with
statins during the trial experienced a significantly lower
cumulative probability of appropriate shocks (15% at 4 years
of follow-up) as compared with statin nonusers (22%;
unadjusted p log-rank  0.01) (Fig. 3B).
Multivariate Cox proportional hazards regression analysis
showed that time-dependent statin therapy was indepen-
dently associated with a 77% (p  0.001) reduction in the
Figure 3 Cumulative Probability for the Occurrence of VT,
VF, Appropriate Shocks, or Death by Statin Treatment
Cumulative probability for the occurrence of VT, VF, appropriate shocks, or
death by statin treatment (A) and the probability for the occurrence of appropri-
ate shock only by statin treatment (B). Follow-up is censored upon change in
statin usage after enrollment. *See Table 3 for multivariate model details.
Abbreviations as in Figure 1.
Multivariate Analysis: Risk Factors for Life-Threatening VentricularTable 2 Multivariate Analysis: Risk Factors for Life-Threatening
Covariate
Fast VT/VF or Death*
HR 95% CI p Value
Time-dependent statin therapy 0.23 0.13–0.40 0.001
Ejection fraction† 0.70 0.58–0.85 0.001
History of prior atrial arrhythmias 2.40 1.38–4.19 0.002
Further adjusted for age, diabetes mellitus, hypertension, left ventricular end systolic volume index
as a VT with a cycle length 320 ms. †Per 5% increase in baseline left ventricular ejection fraction.
CI  confidence interval; HR  hazard ratio; VF  ventricular fibrillation.combined endpoints of fast VT/VF or death, when adjusted
for clinical and echocardiographic parameters (Table 2).
Similar results were observed when the effects of statins on
VF episodes were evaluated and on fast VT/VF; however,
possibly due to sample size limitations, the effect of statin
therapy on this endpoint did not reach statistical signifi-
cance (hazard ratio: 0.57; 95% confidence interval: 0.31 to
1.05, p  0.07). The reduction in the risk of ventricular
arrhythmias was accompanied by an independent 46% (p 
.015) reduction in the risk for the occurrence of appropri-
te device shocks (Table 3).
The reduction in arrhythmic risk associated with statin
herapy was consistent for both the CRT-D and ICD-only
rms (all p values for statin therapy  treatment arm
nteractions 0.10), suggesting that the effect of statin
herapy on the risk of ventricular tachyarrhythmias in
ICM patients was independent of the implanted device.
iscussion
ata regarding the effect of statins on arrhythmic risk in
ICM patients are scarce and limited mostly to 1 sub study
irectly addressing this issue (9).
Our study suggests that statin therapy was associated with
significant reduction in the risk of ventricular tachyar-
hythmias and appropriate defibrillator shocks in patients
ith NICM enrolled in the MADIT-CRT trial.
Antiarrhythmic pleiotropic properties unrelated to the
eduction of ischemic events have been attributed to statins.
hese include the modulation of transmembrane ion chan-
el properties (12), improved heart rate variability due to
eneficial effect on the autonomic tone (13–15), and a
eduction in corrected QT duration and circadian variability
orrected QT dispersion (14,16). It is feasible that the
eduction in ventricular arrhythmias and shock treatment
bserved in our study were due to some or all of these
ffects.
In both the CORONA (Controlled Rosuvastatin Multi-
ational Trial in Heart Failure) (17) and GISSI HF
Gruppo Italiano per lo Studio della Sopravvivenza
ell’Infarto Miocardico–Heart Failure) (18) trials, statin
herapy was not found to be associated with reduction in
udden cardiac death. However, several important differ-
nces exist between the 3 studies, including different inclu-
yarrhythmias in Study Patientstricular Tachyarrhythmias in Study Patients
Endpoint
Fast VT/VF* VF
R 95% CI p Value HR 95% CI p Value
7 0.31–1.05 0.071 0.53 0.29–0.99 0.046
1 0.54–0.92 0.010 0.71 0.55–0.93 0.012
9 0.51–3.27 0.589 1.33 0.53–3.38 0.545
ody surface area and resynchronization treatment. *Fast ventricular tachycardia (VT) was definedTachVen
H
0.5
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ejection fraction lower than 40% due to ischemic etiology
were recruited to the CORONA trial, whereas in the GISSI
HF trial only 35% of the patients had NICM), study patient
age (the patients in both the CORONA and GISSI HF
trials were older than the patients with NICM recruited to
the MADIT-CRT), and outcome evaluation (sudden car-
diac death was a secondary endpoint, and arrhythmias were
not directly evaluated in either trial). Furthermore, in both
the CORONA and GISSI HF trials, rosuvastatin at a dose
of 10 mg was used—a dosage that many believe to be
insufficient to maximize the pleiotropic effects of statins.
Our observation that statin treatment is associated with
slower ventricular arrhythmias is novel. Faster ventricular
tachyarrhythmias have been previously attributed to inflam-
matory states (19). One of the most well-established pleio-
tropic effects of statin is a reduction in inflammation, and
therefore the slower arrhythmia rates could be partially
attributed to this effect. An additional possible explanation
is the modulation of the autonomic tone attributed to statin
treatment. Further studies are needed to confirm this
finding and provide additional underlying mechanisms.
We have recently shown that CRT-D therapy is
associated with a significant reduction in the risk of
VT/VF compared with ICD only among patients who
showed an echocardiographic response to therapy (20).
The present study shows that the effect of statin therapy
on the risk of ventricular tachyarrhythmias was consistent
for patients randomized to either therapy. Thus, treat-
ment with statins might potentiate an already pre-
existing risk-reducing effect of CRT-D on arrhythmic
risk among patients with NICM.
Study limitations. The MADIT-CRT patients were se-
lected for characteristics suggesting the possibility of a
response to resynchronization therapy, and the results might
not be generalizable to a broader NICM patient population.
Statins were prescribed nonrandomly by the treating
physician. In addition, this was an observational analysis of
the MADIT-CRT database, and thus differences between
the baseline characteristics of the patients who were and
were not treated with statins could have affected the occur-
rence of ventricular arrhythmias. Nevertheless, the favorable
effects of statins persisted after multivariate adjustment for
Multivariate Analysis: Risk Factors for Appropriate ICD Shocks in STable 3 Multivariate Analysis: Risk Factors for Appropriate ICD
Appropriate ICD Sh
HR 95% CI
Time-dependent statin therapy 0.54 0.33–0.89
Ejection fraction† 0.77 0.62–0.95
History of prior atrial arrhythmias 1.63 0.81–3.28
*Further adjusted for age, diabetes mellitus, hypertension, left ventricular end-systolic volume inde
ejection fraction.
ICD  implantable cardioverter-defibrillator; other abbreviations as in Table 2.clinical factors.Data regarding individual clinical outcomes were not
provided, because the study sample was not sufficiently
powered to evaluate the separate occurrence of VT or VF.
Although the magnitude of risk reduction associated with
statin therapy was consistent for all endpoints studied, the
effect of statin therapy on the risk of the endpoint of fast
VT/VF only did not reach statistical significance. These
findings might be due to sample size limitations or to the
fact that some lethal events (which were not included in this
endpoint) were due to arrhythmic events.
Conclusions and Clinical Implications
Statins have also been suggested to exert direct antiarrhyth-
mic effects, in addition to reduction in the risk of recurrent
ischemic events. In this study, we extend these prior
findings and show that treatment was associated with a
significant reduction in the risk of ventricular arrhythmias
for patients with NICM. In addition, our data suggest that
statin treatment is associated with a slower cycle length at
the time of the arrhythmia and with a lower incidence of
VT/VF, regardless the implanted device-type. Additional
studies, preferably performed in a randomized fashion, are
needed to confirm these findings.
Reprint requests and correspondence: Dr. Jonathan Buber,
Leviev Heart Center, Chaim Sheba Medical Center, Tel
Hashomer 52621, Israel. E-mail: yonibuber@gmail.com.
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